

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 63 Years	3. SEX Female	3a. WEIGHT 66.00 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input checked="" type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING
		Day	Month	Year			Day	Month	Year		
		PRIVACY					19	JAN	2024		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
Other Serious Criteria: med sig
Cancerous sarcoma in the left leg/large lump [Malignant neoplasm progression]
Anal irritation [Anorectal discomfort]
Fall [Fall]
Diarrhea [Diarrhoea]
She has not been hungry (lack of appetite) [Decreased appetite]
Vomiting [Vomiting]
Dizzy [Dizziness]

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Abemaciclib (Abemaciclib) Tablet		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
(Continued on Additional Information Page)		
15. DAILY DOSE(S) #1) 150 mg, bid	16. ROUTE(S) OF ADMINISTRATION #1) Oral	21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
17. INDICATION(S) FOR USE #1) Breast Cancer (Breast cancer)	18. THERAPY DATES(from/to) #1) 10-DEC-2023 / Unknown	
19. THERAPY DURATION #1) Unknown		

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) #1) IRON (IRON) Unknown ; Unknown #2) VITAMIN C [ASCORBIC ACID] (VITAMIN C [ASCORBIC ACID]) Unknown ; Unknown #3) CALCIUM (CALCIUM) Unknown ; Unknown #4) ARIMIDEX (ANASTROZOLE) Unknown ; Unknown #5) VERSATIL (ROFECOXIB) Unknown ; Unknown		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Unknown		

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Eli Lilly Interamerica Inc (AR Branch) Tronador 4890 - Piso 12 Buenos Aires, Capital Federal CP: 1430 ARGENTINA Phone: 54 1145464000		26. REMARKS
	24b. MFR CONTROL NO. CR202401015858	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD. NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 07-MAY-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 13-MAY-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

13-May-2025 19:06

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

Case Description: This solicited case, reported by a consumer who contacted the company via business partner and patient support program (PSP), with additional information from initial reporter, concerned a 63-year-old female patient of an unknown origin.

Medical history was not provided. Concomitant medications included, iron, vitamin c, rofecoxib and calcium; all for an unknown indication.

The patient received abemaciclib (Verzenio) tablet, 150 mg twice a day, orally, for the treatment of breast cancer, beginning on 10-Dec-2023. She also received, anastrozole as concomitant chemotherapy. On 01-Jan-2024, 23 days after starting abemaciclib therapy, she experienced diarrhea of moderate severity and took loperamide hydrochloride as a corrective treatment beginning on 10-Jan-2024. She was also scheduled for an appointment with a nutritionist. On an unknown date in Jan-2024, she had not eaten lunch because she had not been hungry due to lack of appetite. On an unknown date, she spent the whole day without hunger. Sometimes she ate until the afternoon or a little at lunch but did not eat much. On 19-Jan-2024, she had vomiting and diarrhea. On 20-Jan-2024, she felt dizzy. On 22-Jan-2024, she had about seven diarrheas. On 23-Jan-2024, she also had several diarrheas and felt like she had an anal irritation. On 24-Jan-2024, she went to the bathroom seven times. On 25-Jan-2024, she went early in the morning for diarrhea and then at 11 am again. In the morning time diarrhea occurred most. On 10-Apr-2024, she had fallen from her own height, did not know what was wrong because she did not lose consciousness, clarified that it was not a fainting spell. Since an unknown date, she had a very large lump and got operated to remove it and took it for a biopsy. After one month of the operation, she found that she had a severe cancerous sarcoma in the left leg due to which she got hospitalized and underwent a surgery sometime in Oct-2024 as a corrective treatment. The event of malignant neoplasm progression was considered as serious by reporter due to medically significant reason. Since an unknown date sometime in Apr-2025, she started to receive radiation therapy for one month and completed it. She would also wait for the magnetic resonance imaging. Information regarding corrective treatment for remaining events was not provided. Outcome of the event malignant neoplasm progression was unknown while it was not resolved for remaining events. Abemaciclib therapy was ongoing.

The initial reporting consumer did not provide the relatedness assessment of the events with abemaciclib therapy.

Update 05-Feb-2024: Additional information was received from initial reporter via PSP on 29-Jan-2024. Added one dosage regimen, concomitant medications, four non-serious events of anorectal discomfort, decreased appetite, vomiting and dizziness. Updated narrative with new information.

Update 15-May-2024: Additional information was received from initial consumer reporter via business partner and PSP on 09-May-2024. Added one non-serious event of fall. Updated onset date of event diarrhea and the narrative with new information.

Update 12-May-2025: Additional information was received from initial consumer reporter via business partner and PSP on 07-May-2025 and this case had been upgraded upon the addition of serious event of malignant neoplasm progression. Added patient demographics (weight) and a concomitant medication of rofecoxib. Updated the narrative with new information.

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Biopsy		
		Of lump removed. Cancerous sarcoma found.		

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Abemaciclib (Abemaciclib) Tablet; Regimen #2	150 mg, bid; Oral	Breast Cancer (Breast cancer)	19-JAN-2024 / Ongoing; Unknown